EX-FILING FEES 12 d825007dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

SC TO-T

(Form Type)

Deciphera Pharmaceuticals, Inc.

(Name of Subject Company - Issuer)

Topaz Merger Sub, Inc.

(Names of Filing Persons - Offeror)

Ono Pharmaceutical Co., Ltd.

(Names of Filing Persons - Parent of Offeror)

Table 1: Transaction Valuation

 

       
    

 Transaction 

Valuation

 

Fee

 Rate 

 

 Amount of 

Filing Fee

       

Fees to Be Paid

  $2,426,954,563*   0.00014760   $358,218**
       

Fees Previously Paid

  $0.00     $0.00
       

Total Transaction Valuation

  $2,426,954,563      
       

Total Fees Due for Filing

      $358,218
       

Total Fees Previously Paid

      $0.00
       

Total Fee Offsets

      $0.00
       

Net Fee Due

          $358,218

 

*

The transaction valuation was estimated based on the sum of (a) the product of 82,225,972 shares of common stock issued and outstanding and $25.60 per share; (b) the product of 6,980,932 shares of common stock underlying outstanding options, with exercise prices less than $25.60, and $12.524, which is the difference between $25.60 and the weighted average exercise price of $13.076 per share of the underlying outstanding stock options; (c) the product of 3,085,820 shares of common stock underlying outstanding restricted stock unit awards and $25.60 per share; (d) the product of 530,544 shares of common stock underlying outstanding performance stock unit awards and $25.60 per share; (e) the product of 5,466,133 shares of common stock underlying outstanding pre-funded warrants, and $25.59, which is the difference between $25.60 and the weighted average exercise price of $0.01 per share of the underlying outstanding pre-funded warrants; and (f) the product of 81,376 shares of common stock estimated to be issued under the Company ESPP and $25.60 per share. The calculation of the filing fee is based on information provided by Deciphera Pharmaceuticals, Inc. as of April 24, 2024.

**

The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #1 for fiscal year 2024 beginning on October 1, 2023, issued on August 25, 2023, by multiplying the transaction valuation by 0.00014760.